Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME The Company will now target five major cancer types with its four...
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME Two oral presentations and...
Immatics Announces Pricing of $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical...
Immatics Announces Proposed $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical...
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial Company to host conference...
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V...
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development...
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”...
Immatics Announces Second Quarter 2024 Financial Results and Business Update Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients...
Immatics Appoints Alise Reicin to Board of Directors Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.045 | 0.647016534867 | 6.955 | 7.39 | 6.845 | 4757 | 7.03174129 | DE |
| 4 | -0.45 | -6.04026845638 | 7.45 | 7.48 | 6.495 | 6900 | 6.87302548 | DE |
| 12 | -1.59 | -18.509895227 | 8.59 | 9.32 | 6.495 | 5029 | 7.55925177 | DE |
| 26 | -3.96 | -36.1313868613 | 10.96 | 12.01 | 6.495 | 3899 | 8.75289063 | DE |
| 52 | -2.6199999 | -27.2349264785 | 9.6199999 | 12.6 | 6.495 | 3470 | 9.72619777 | DE |
| 156 | -3.9 | -35.7798165138 | 10.9 | 13.2 | 6.15 | 3250 | 9.61967512 | DE |
| 260 | -3.64 | -34.2105263158 | 10.64 | 13.2 | 6.15 | 3076 | 9.63329874 | DE |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
